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Abstract
Background: Locoregional recurrence (LRR) is an important factor after pancreaticoduodenectomy (PD) for pancreatic cancer. IORT administered to the resection bed may improve local
tumor control.
Methods: We performed a retrospective analysis of patients who underwent PD at Thomas
Jefferson University Hospital (TJUH) between 1995 and 2005 to identify patients who underwent
resection with and without intraoperative radiation therapy (IORT). Data collected included age,
gender, complications, margin status, stage, survival, and recurrence. Unadjusted analyses of
the IORT and non-IORT groups were performed using Fisher’s chi-square method for discrete
variables and Wilcoxon Rank Sum test for continuous variables. To account for biases in patient
selection for IORT, a propensity score was calculated for each patient and adjusted statistical
analyses were performed for survival and recurrence outcomes.
Results: Between January 1995 and November 2005, 122 patients underwent PD for perimpullary
tumors, including 99 pancreatic cancers. Of this group, 37 patients were treated with IORT, and
there was adequate follow-up information for a group of 46 patients who underwent PD without
IORT. The IORT group contained a higher percentage of Stage IIB or higher tumors (65%)
than in the non-IORT group (39.1%), though differences in stage did not reach significance
(p = 0.16). There was a non-significant decrease in the rate of LRR in patients who had IORT (39%
non-IORT vs. 23% IORT, p = 0.19). The median survival time of patients who received IORT was
19.2 months, which was not significantly different than patients managed without IORT, 21.0
months (p=0.78). In the propensity analyses, IORT did not significantly influence survival or
recurrence after PD.
Conclusions: IORT can be safely added to management approaches for resectable pancreatic
cancer, with acceptable morbidity and mortality. IORT did not improve loco-regional control and
did not alter survival for patients with resected pancreatic cancer. IORT is an optional component
of adjuvant chemoradiation for pancreatic cancer. In the future, IORT may be combined with
novel therapeutic agents in the setting of a clinical trial in order to attempt to improve outcomes
for patients with pancreatic cancer.
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Surgical resection is an essential component
in the therapeutic approach to patients with
localized pancreatic cancer. Despite refinements in surgical technique, local and distant
recurrences are common. Long-term survival
rates are low for patients with resectable
tumors, with 15-20% 5-year survival reported
among patients who undergo pancreaticoduodenectomy (PD) alone.1, 2 In a review of
resection margins of 72 patients who underwent PD, Willett et al. detected a positive margin in 51% of cases; this factor was associated
with inferior survival and local control when
compared with those patients with negative
surgical margins.2 Although there is controversy
regarding the appropriate components of
adjuvant management of resected pancreatic
cancer,3-7 outcomes achieved after surgery
alone continue to be poor; therefore, the need
remains for adjuvant therapy to improve local
control and survival.3-8 In the United States,
adjuvant chemoradiotherapy (CRT) is performed
as part of the standard therapeutic paradigm,
based on the recurrence patterns of pancreatic
cancer after surgery.8, 9
Intraoperative radiation therapy (IORT), the
delivery of a single, large dose of irradiation at
the time of surgery, was developed in order
to administer higher doses of irradiation while
displacing or shielding adjacent normal tissue
structures from radiation exposure .10 In pancreatic
cancer, IORT has been offered for unresectable tumors to provide local tumor control
and palliation of pain,11-16 and for resectable
tumors in an effort to improve local control
and survival after PD.11-19 Although a definitive
survival benefit has not been observed,
improvement of local control by IORT at the
time of PD for resectable pancreatic cancer is
supported by retrospective data, as well as by a
prospective, randomized trial conducted at the
National Cancer Institute (NCI).19-21

Studies

At our institution, IORT has been offered since 1986 in a dedicated
operating suite located in the radiotherapy department for patients with
either resectable or unresectable pancreatic cancer. IORT was considered for
all patients undergoing PD at our institution until 1998. Since then, IORT
has been reserved for patients with larger tumors with higher risk of
positive margins, as visualized by the surgeon on preoperative imaging.
Prior reports from our institution have described outcomes of patients
who received IORT for resectable and unresectable pancreatic cancer
prior to 1995.13, 22 The current study evaluates outcomes for patients who
received treatment for resectable pancreatic cancer from 1995 to 2005.
As a result of physician bias for the use of IORT in more advancedstage pancreatic cancer at our institution, it was not possible to identify
a comparative group of patients for use in a matched pair analysis.
Therefore, in order to account for the biases inherent in the nonrandom
treatment assignment for patients in the current study, analyses of
survival and recurrence were adjusted using propensity scoring.23 In this
way, we attempted to minimize the influence of confounding patientand tumor-related variables in order to assess the contribution of
IORT to local tumor control and survival of patients with localized,
resectable pancreatic cancer treated at our institution.

Materials & Methods
A prospective tumor registry database was searched to identify all
patients who underwent PD at Thomas Jefferson University during
1995-2005. The study was performed with approval of the institutional
review board at Thomas Jefferson University. These patients were
further divided into those who did and did not receive IORT. We
collected data regarding age, gender, margin status, stage, survival and
recurrence. Loco-regional recurrence (LRR) was defined as recurrence
within the tumor bed or regional lymph nodes. Systemic recurrence
(SR) consisted of recurrence in the liver, peritoneum, lungs, bone, or
other distant site. Overall survival (OS) and time to LRR were measured
from the date of surgery. Given the institutional bias towards IORT for
larger tumors during much of the study period, a difference between
treatment groups was anticipated in the statistical analysis. A propensity
score, a statistical method to adjust for nonrandom treatment decisions
in observational studies, was also calculated for each patient using a
logistic regression model.23

Treatment Policy
All patients were treated according to institutional treatment policies
during 1995-2005. As a general rule, IORT was considered for all
patients prior to 1998 and subsequently for patients with larger tumors
based on review of preoperative imaging by the attending surgeon. For
these patients, surgery was performed in an operating room located
in the radiation oncology department, an arrangement selected to
facilitate IORT delivery. IORT was delivered using 6-15 MeV electrons
and cone sizes selected in order to deliver a dose of 10-20 Gy to a field
encompassing the pancreatic tumor bed within the 90% isodose line.
Regional lymph nodes were not included in the target volume for
most cases. The cone size, treatment set-up, and immobilization were
selected in order to treat the target volume while minimizing exposure
of adjacent normal tissue structures. The standard dose, 15 Gy, was
reduced to 10 Gy for either large treatment volumes or margins that
were clearly negative. For larger tumors, 20 Gy was often prescribed.
In cases where adjuvant external beam radiation therapy (RT) was
also delivered, a dose of 45-50.4 Gy was prescribed using a conformal,
four-field radiation technique.

Statistical Analysis
Simple descriptive statistics were generated, and unadjusted associations
with IORT were determined using Fisher’s Chi Square test for categorical
variables and using the Wilcoxon rank sum test for continuous variables.
The propensity score, which was calculated for all patients included in
the analysis using a logistic regression model, included resection status,
AJCC Stage, differentiation, age, race, and sex. Propensity scores were
incorporated as a categorical variable in the statistical analyses based
on quartiles. The association of IORT with the primary outcome of
survival was determined using a Cox proportional hazards model.
The Cox proportional hazards model included IORT, the propensity
score (by quartile), adjuvant chemotherapy, and adjuvant radiotherapy.
Association of IORT with the secondary outcomes of any recurrence,
loco-regional recurrence, and systemic recurrence was determined using
logistic regression models. Included in the logistic regression models for
adjusted analyses of recurrence were IORT, the propensity score (by
quartile), adjuvant chemotherapy, and adjuvant radiotherapy.

Results
From January 1995 to November 2005, 122 patients underwent PD for
periampullary tumors, including 99 pancreatic cancers. We identified
37 patients with pancreatic cancer who were treated with IORT. Among
the remaining 62 patients with pancreatic cancer treated without IORT,
adequate follow-up data could be obtained for 46 patients, who comprised
the non-IORT group used in the statistical analyses. The median patient
age in the IORT group was 64 years (inter-quartile range, 55-70 years); in
the non-IORT group, the median age was 67 years (inter-quartile range,
59-74 years). The IORT group demonstrated non-significant trends
toward more advanced stage tumors (p=0.16) and a higher rate of positive
margins (p=0.26). A higher proportion of patients received adjuvant
chemotherapy after PD with IORT than after PD alone (p=0.05) (Table 1).
There were 2 perioperative deaths in the IORT group (5.4%) and none in
the non-IORT group (p=0.20). Rates of perioperative complications were
similar, 46% in the IORT group versus 40% in the non-IORT group. The
median follow-up among surviving patients was 21 months.

Recurrence and Survival
Recurrence data were available for 80% of all patients, including 30 IORT
patients (81%) and 36 non-IORT patients (78%). Rates of loco-regional
recurrence (LRR) (Figure 1) or any recurrence (Figure 2) were not
significantly different between the IORT and non-IORT groups. Among
non-IORT patients, there was loco-regional recurrence (LRR) in 39%,
systemic recurrence (SR) in 50%, and any recurrence in 69%. In the
IORT group, LRR in 23%, SR in 57% of patients, with, and recurrence
was observed in 67% (Table 2). Liver metastases were the most common
form of SR. LRR in the absence of SR was observed in 2 patients (7%)
in the IORT group and in 7 patients in the non-IORT group (19%). LRR
was not significantly different between the IORT and non-IORT groups
(p=0.20). The median survival time of patients undergoing IORT was
19.2 months, which was not significantly different than patients managed without IORT, 21.0 months (p=0.49) (Figure 3).

Propensity Score Analysis
In the adjusted, propensity score analysis of the association of IORT
with survival, IORT was not associated with significant improvement of
survival time (Table 3). The Cox regression model for survival included
IORT status with propensity score (by quartile), as well as adjuvant RT and
chemotherapy. The propensity score-adjusted analyses of the association
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Table 1. Tumor- and treatment-related characteristics for
37 IORT patients and 46 non-IORT patients with resected
pancreatic cancer.
PD + IORT
[n (%)]

PD (No IORT)
[n (%)]

I

7 (19)

16 (35)

IIA

6 (16)

12 (26)

≥IIB

24 (65)

18 (39)

Factor

Stage

Margin Status

RO

21 (57)

32 (70)

R1/R2

16 (43)

14 (30)

7 (19)

8 (18)

Moderate

21 (58)

25 (56)

Poor

8 (22)

12 (27)

Adjuvant
Chemotherapy
(n=79)

Yes

26 (84)

27 (63)

No

5 (16)

16 (37)

Adjuvant EBRT
(n=75)

Yes

23 (74)

29 (66)

No

8 (26)

15 (34)

(n=81)

0.16

PD + IORT
[n (%)]

PD (No-IORT)
[n (%)]

7 (23)

14 (39)

Locoregional

0.26

Tumor Bed

6 (20)

8 (22)

Lymph Node

4 (13)

10 (28)

Locoregional-Only
Liver

0.91

0.05

0.44

of IORT with LRR, with SR, and with any recurrence were conducted
using logistic regression models (Table 4). After adjusting for propensity
score quartile and for adjuvant therapies, IORT did not influence recurrence rates after PD for pancreatic cancer. A non-significant trend towards
higher rates of any recurrence was noted for propensity scores in the third
(OR 9.66, p = 0.14) or fourth quartile (OR 9.64, p = 0.15).

Discussion
Local control was not significantly different between the two groups,
IORT and non-IORT, evaluated in the current series. Although the
current study is limited by its retrospective design and institution bias
towards treating more advanced tumors with IORT, an attempt was

2 (7)

7 (19)

17 (57)

18 (50)

11 (37)

11 (31)

Lung/Pleura

4 (13)

7 (19)

Systemic-Only

14 (47)

11 (31)

made to account for nonrandom allocation of patients into the IORT
and non-IORT groups by using propensity score values in adjusted
statistical analyses of the association of IORT with survival and recurrence.
Adjuvant chemotherapy was administered to more patients in the
IORT group. Although information concerning decision-making was
not available, the increased rate of chemotherapy may be related to the
presence of more advanced tumors in the IORT group. Despite the trends
toward more advanced-stage tumors and positive resection margins in
the IORT group, similar local control rates were observed.
The disparities in stage and margin status in the current study may have
obscured any potential local control benefit of IORT, as these factors have
been reported to negatively influence survival for patients with resected
pancreatic cancer.24, 25 Prior retrospective, single-institution reports
suggest that IORT improves local control after PD by approximately
30%.19, 21 In this study, LRR was 50% less in the IORT group. In the
prospective, randomized trial conducted at the NCI, local control
improved from 0% to 33% with the addition of IORT.20 In a recent series

1.0
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1.0
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Figure 1. Kaplan-Meier plot of locoregional failure for patients
treated with (solid line) and without (dashed line) IORT (p = 0.20).

20

Site of First Recurrence

Systemic

Well

Grade

p value

Table 2. Location of first recurrence. Thirty patients in the IORT
group and 36 patients in the non-IORT group were included in
the recurrence analysis, based on availability
of data to determine site of recurrence.
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Figure 2. Kaplan-Meier plot of recurrence (any site) for patients
treated with (solid line) and without (dashed line) IORT (p = 1.0).

Studies

Table 2. Location of first recurrence. Thirty patients in
the IORT group and 36 patients in the non-IORT group were
included in the recurrence analysis, based on availability
of data to determine site of recurrence.
Site of First Recurrence

Table 4. Logistic regression models of the association of IORT,
propensity score, and other factors, with the outcomes of any
recurrence, locoregional occurrence, and systemic recurrence.
Odds Ratio

PD + IORT
[n (%)]

PD (No-IORT)
[n (%)]

7 (23)

14 (39)

Locoregional
Tumor Bed

6 (20)

8 (22)

Lymph Node

4 (13)

10 (28)

Locoregional-Only
Systemic

2 (7)

7 (19)

17 (57)

18 (50)

Liver

11 (37)

11 (31)

Lung/Pleura

4 (13)

7 (19)

Systemic-Only

14 (47)

11 (31)

95% CI

p

Any Recurrence

IORT

0.77

(0.19, 5.20)

0.72

Adjuvant Chemotherapy

1.69

(0.15, 19.29)

0.67

Adjuvant Radiotherapy

1.11

(0.11, 11.68)

0.93

Propensity Score (vs. 1st Quartile)
2nd Quartile

1.22

(0.33, 4.52)

0.76

3rd Quartile

9.66

(0.47, 197.40)

0.14

4th Quartile

9.64

(0.46, 203.31)

0.15

IORT

0.41

(0.10, 10.30)

0.23

Adjuvant Chemotherapy

0.49

(0.02, 11.37)

0.65

Adjuvant Radiotherapy

1.74

(0.86, 35.51)

0.72

Locoregional Recurrence

from the City of Hope National Medical Center, isolated local recurrences were reduced from 33% to 5% with the addition of IORT, which
is comparable to the rate of isolated LRR in the current report (7%).24
Reni et al. reported a similar alteration of recurrence patterns, with 15%
local-only recurrences with IORT versus 33% without IORT.26 The
cumulative evidence, including one prospective randomized trial and a
few prospective studies, supports a local control benefit for IORT in
resectable pancreatic cancer. An improvement in local control has not
been shown to translate into a clinical benefit in survival outcomes,
including in this study. Although a propensity score analysis was
performed in the current study to evaluate the influence of IORT on
recurrence rates after PD, the limited size of the patient population may
have restricted our ability to detect a significant positive effect.
The survival rates were not different between the IORT and non-IORT
groups in the current series, which is consistent with the results of
the prospective NCI study.20 Given the propensity of pancreatic cancer
towards distant metastatic recurrence, it is not surprising that a measurable
increase in local control did not produce a corresponding improvement
of survival.27 Although some authors report a survival benefit
from IORT for resectable pancreatic tumors at their institutions, the
literature does not consistently support this claim, and detection of a

Table 3. Cox proportional survival hazard model for
the association of IORT, propensity score, and other
factors with survival time in months.
Estimate

Standard
Error

Chi-Square

Hazard
Ratio

p

IORT

-0.34

0.35

0.94

0.71

0.33

Adjuvant
Chemotherapy

0.51

0.73

0.48

1.66

0.49

Adjuvant
Radiotherapy

-1.05

0.68

2.39

0.35

0.12

Propensity Score (vs. 1st Quartile)
2nd Quartile

-0.68

0.45

2.35

0.50

0.13

3rd Quartile

0.55

0.49

1.26

1.73

0.26

4th Quartile

0.58

0.47

1.56

1.79

0.21

Propensity Score (vs. 1st Quartile)
2nd Quartile

0.39

(0.02, 7.47)

3rd Quartile

5.13

(0.73, 36.03)

0.53
0.10

4th Quartile

3.32

(0.46, 23.93)

0.23

0.99

(0.28, 3.52)

0.99

Systemic Recurrence

IORT
Adjuvant Chemotherapy

0.40

(0.03, 6.42)

0.52

Adjuvant Radiotherapy

1.30

(0.10, 16.96)

0.84

Propensity Score (vs. 1st Quartile)
2nd Quartile

1.11

(0.23, 5.40)

0. 90

3rd Quartile

0.91

(0.16, 5.13)

0.91

4th Quartile

0.59

(0.10, 3.50)

0.56

potential small survival benefit would require a large trial.19, 22, 24, 26, 28, 29
Regardless of the absence of improved survival, the problem of
locoregional control does leave open a place for radiation therapy after
PD, and IORT is an effective technique to boost radiation dose around
the resection bed while displacing sensitive adjacent organs.8, 10, 17, 30 A
recent analysis of the Surveillance, Epidemiology, and End Results database revealed a survival benefit to the addition of adjuvant radiotherapy
after PD, and radiation therapy remains an important component of
adjuvant strategies in the United States.25 Results recently published
from the Radiation Therapy Oncology Group (RTOG) trial 9704, the
first cooperative group study to require prospective quality assurance of
radiotherapy, suggest a benefit to the addition of gemcitabine to adjuvant
CRT after PD. The rates of first relapse in local and regional sites in the
experimental arm of RTOG 9704 were 23% and 7%, respectively..31
Importantly, the addition of IORT after PD did not increase perioperative complication rates significantly in the current series, which is
consistent with the earlier experience from our institution.22 Although
late complications have been reported after IORT for pancreatic cancer,
our results and other reports suggest that IORT may be delivered
safely in combination with surgical resection.24, 26, 28, 32, 33-37 Selection of
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